PRESENTATION

AGM 29th October 2013

PharmAust LIMITED

ASX: PAA

ACN 094 006 023

ABOUT PAA FOLLOWING ACQUISITION OF PITNEY PHARMACEUTICALS LIMITED

PHARMAUST LIMITED

ASX:PAA

ABOUT PAA FOLLOWING ACQUISITION OF PITNEY PHARMACEUTICALS LIMITED CONT.

Peloton Capital, PharmAust's Corporate Adviser, successfully completed a heavily oversubscribed Placement and then a SPP in Aug/Sep 2013

Total Cash Raised $3.5M

Many Changes Recently – What Does PharmAust now Do?

1. It is not our intention to take new drugs from the bench to the market place which often now takes **12 YEARS** to achieve and 100s of millions of dollars
2. We are also not interested in copying other peoples drugs to create generics – perfect copies of existing drugs **(3-4 YEARS)** – too many competitors out of Asia
3. **WHAT WE LIKE TO DO IS TO FIND NEW USES FOR OLD DRUGS (OR NEWLY LAUNCHED DRUGS) BY OTHER COMPANIES – WE CAPITALISE ON THE SUBSTANTIAL INVESTMENTS ALREADY MADE ON DRUGS BUT PREMIUM PRICE BY PATENTING NEW USES**

PAA FOLLOWING ACQUISITION OF PITNEY PHARMACEUTICALS PTY LIMITED

Oncology Focus

Phase II Clinical Stage

Strategic Partnerships with two Global Corporations

- Targeting oncology applications of well established drugs and "piggy-backing" on substantive programmes of major pharmaceutical companies
- Identifying highly specific clinical needs in oncology
- Engaging a leading clinical oncology unit (St George Hospital, Sydney)
- Granted patents or patent filings (either owned outright or jointly with partner)
- Relationships with major global corporations
- Use of CROs and external R&D suppliers

Pitney Pharmaceuticals
Foundations & Commercial Cornerstones

NEW SOUTHWALES INNOVATIONS

Strategic Alliances Global Corporations

UNSW AUSTRALIA

THE ST. GEORGE HOSPITAL SYDNEY

PPL Pitney Pharmaceuticals Pty Limited

IP - Granted and Pending Patents

The Technology Pipeline

PPL-1 Drug (Platform 1)	• a new patent focuses on the very low side-effect profile of the drug for use in oncology (multiple cancers).
Albendazole (ALB) (Platform 2)	• drug used extensively in human and veterinary practice • shown to be a potent Vascular Endothelial Growth Factor (“VEGF”) inhibitor
Diseases involving mucin (Platform 3)	• this third cancer product area involves the use of specific enzymes to challenge the ability of certain tumours to have resistance to chemotherapy

Platform 1 PPL-I Anthelminthic Drug

New Drug from Pharma Industry

- A veterinary product to treat parasites in farm animals found by Pitney to be potent in killing human tumours in animal models
- PPL has secured IP through recent patent filings on the use of PPL-I in cancer
- No drug related specific signs of toxicity even in high single and repeated dose studies in the various mammalian species (mouse, rat, rabbit, dog, sheep)
- Novel mechanism for killing cancer cells uniquely different from traditional chemotherapeutics
- PPL has signed a Research and Option (Licence) Agreement with global animal health company owned by major Pharma

Effect of Drug in Cancer Cells I

LN-18 is glioma cell line resistant to Temozolomide



PPL-I

NORMAL CELLS



PPL-I

Effect of Drug in Cancer Cells II

Temozolomide resistant Giloma U251, DRUG PPL-I treated



Temozolomide resistant Giloma U251, Temozolomide treated for 72 hours



- Similar to U87, U251 glioma cells are highly sensitive to DRUG treatment.

Effect of Drug in Mice

Dose-finding study of IP administered Drug in nude mice bearing Subcutaneous ovarian tumors (OVCAR-3), SC / IP

Control group
Vehicle, 0.5% HPMC

Low dose group
25 mg / kg
DRUG

PPL-I

High dose group
50 mg / kg
DRUG

PPL-I

Platform 2 – ALBENDAZOLE (ALB)

- Has completed two phase I/II studies in patients with late stage ascites
- Extensive existing safety data for albendazole exists from both human and veterinary use
- Manufacturing to regulatory standards is established by third parties (marketed as Albenza and several other brands for oral use)
- Targeted to the treatment of ascites by localised therapy to abdomen

Albendazole Ascites I



Fig. 1. Effect of albendazole (*ABZ*) on ascites development. Nude mice inoculated i.p. with OVCAR-3 cells were left to develop ascites and then randomly assigned to one of control or albendazole treatment groups (n = 10 per group). Whereas all mice in the control group developed overt ascites, there were no macroscopic signs of ascites formation in albendazole-treated mice.



Fig. 3. Survival curve showing the effect of albendazole (*ABZ*) on survival. Whereas for all animals the intended duration of treatment was 4 weeks, mice (10 per group) were euthanized if due to ill health, they were expected to become moribund within a short time. Survival was calculated as the number of days lapsed between initiation of treatment and eutharasia, and % mice surviving was the number of animals remaining in each group (×10) at the end of each week following initiation of treatment.

Ascites in Man



Diagram showing fluid in the abdomen



Epichem PTY LTD



- Wholly owned by PharmAust Ltd (ASX: PAA)
- Formed in October 2003
- Core skills are synthetic & medicinal chemistry
- Drug discovery company / contract research lab
- Currently have 14 employees (9 PhD)
- Managing Director Dr Wayne Best
- Laboratories in Perth & Melbourne
- Multiple Awards

Epichem's Business Model

Cashflows

- Generate positive cashflow by providing products and services from our core expertise in synthetic and medicinal chemistry

IP

- Fund our own research from this cashflow to generate valuable IP

Commercialise / Partner the IP

- Commercialise or partner the IP as soon as possible (preclinical)

Epichem's Revenues & Profits



EpiChem Management

Dr WAYNE BEST

Managing Director (Founder)

Wayne has over 30 years experience in synthetic and medicinal chemistry both in academia, government and industry. He obtained his PhD from The University of WA and followed with postdoctoral studies at both Imperial College London and The Australian National University Canberra.

Wayne is a Fellow of the Royal Australian Chemical Institute and an Adjunct Associate Professor at The University of WA. He is also a Graduate of the Australian Institute of Company Directors and has been a Director of a number of biotechnology companies and spent 2 years as the WA Branch Chair of AusBiotech.

Dr MARTINE KEENAN

Head of Drug Discovery

Dr Keenan is a medicinal chemist with over 10 years professional experience in drug discovery, including 8 years with Eli Lilly in the UK. Following a PhD in natural products synthesis at Kings' College in London, and post-doctoral studies in Germany developing chiral catalysts for asymmetric hydrogenation.

Martine has expertise in identifying novel hits, designing new analogues, computer-aided drug design, using SAR analysis to develop compounds into new leads and optimising molecules towards drug candidates.

Martine moved to Perth and joined Epichem in 2008 working primarily in the field of infectious diseases and managing drug discovery projects.

85% of Revenues from Export

48th Australian Export Awards
WINNER



PharmAust Commercial Programme and Milestones for 2013/2014 - 1

PPL-1

1. Initiation of Trials in Dog Cancers (Australia/UK)
2. Initiation of Phase I/II in man (St George Hospital)
3. Exercise of Option by Licence by Partner
4. Identification of Licensee for Human Applications
5. Phase II Efficacy Trial
6. Potential to sign second Licence Agreement

PharmAust Commercial Programme and Milestones for 2013/2014 - 2

1. Initiation of Optimisation trial of ALB in man (St George Hospital)
2. Filing of IND with FDA
3. Identification of Licence Partner for ALB in Ascites
4. Phase II/III registration trial in Ascites patients

PharmAust Commercial Programme and Milestones for 2013/2014 - 3

1. Growth in sales and Profitability of Epichem
2. Patenting a novel class of compounds for the treatment of diabetes

Board of Executives

DR ROGER ASTON

Executive Chairman

Previously at the Wellcome Research Laboratories, now Glaxo, Peptech Limited (CEO) (Arana acquired by Cephalon), Cambridge Antibody Technology (Director) (acquired by Astra Zeneca). Also, UK Government's Defence Evaluation and Research Agency (now QinetiQ Ltd) co-founder pSivida Limited (Australia ASX:PSD – now PVA on NASDAQ). Dr Aston has also held Directorships/Chairmanships with Clinuvel Limited (ASX:CUV), HalcyGen Limited (ASX:HGN) and Ascent Pharma Health Limited (recently sold to Watson USA). During 2007 and 2008, Dr Aston was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board. More recently, Dr Aston was CEO of Mayne Pharma Group.

PROFESSOR DAVID MORRIS

Director and Chief Scientific and Clinical Officer

Head Department of Surgery, Faculty of Medicine, St. George's Hospital, Sydney, University of NSW. Academic Surgeon, Head of UNSW Department >20 years with almost 700 peer review publications.

MR SAM WRIGHT

Director & Company Secretary

Sam Wright is experienced with ASX listed companies, corporate governance and corporate finance. He joined the Company as Financial Controller in 2006, and subsequently appointed as Company Secretary and Director. Mr Wright is currently Company Secretary of ASX listed companies, Buxton Resources Limited, Cove Resources Limited, PharmAust Limited and Structural Monitoring Systems plc. He is the director of Perth-based corporate advisory firm Straight Lines Consultancy, specialising in the provision of corporate services to public companies.

Board Evolution

ROBERT BISHOP

Executive Director

Robert has 30 years experience in corporate finance and equity capital markets having worked extensively in London and Sydney, first as a lawyer at Linklaters & Paines and Allen, Allen & Hemsley; and then as a stockbroker and investment banker at Ord Minnett, Robert Fleming and, since 1998, at his Sydney based corporate finance business, First Capital Markets. He has extensive experience in the areas of stock market flotation's, licensing, compliance and fundraising.

Contact Details

MR SAM WRIGHT

Director & Company Secretary (PAA)
Email: sam@straightlines.net.au
Phone: 0408 900 277

DR ROGER ASTON

Managing Director (PPL)
Email: rogeraston@aol.com
Phone: 0402 762 204

Disclaimer

- This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes an offer, invitation , solicitation or recommendation in relation to the purchase or sale of shares.

- Shareholders should not rely on this presentation. This presentation does not take into account any persons particular investment objectives, financial resources or other relevant circumstances and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons.

- The information set out in this presentation does not purport to be all inclusive or to contain all the information which its recipients may require to make an informed assessment of the proposed transaction. You should conduct your own investigations and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation.